Shape the future of T1D. Add your voice and type 1 hope now.
Click Here
Uncategorised

Baricitinib in New Onset Type 1 Diabetes (BANDIT)

Please note that all applications to participate in the BANDIT trial will be assessed, but the trial has almost reached its maximum participant capacity, your place in the trial cannot be guaranteed.
Thank you for your interest and understanding.

BANDIT is a clinical trial testing a drug called baricitinib that has the potential to slow or stop the destruction of beta cells in people with T1D.

Participants in the BANDIT trial must be between the ages of 10 – 30 years old, and must have been diagnosed with type 1 diabetes within the last 100 days.

Participants will be required to attend at one of four sites in Melbourne or Adelaide: The Royal Melbourne Hospital, The Royal Children’s Hospital, St Vincent’s Hospital Melbourne or the Women’s and Children’s Hospital Adelaide.

BANDIT has been approved by the Melbourne Health Human Research Ethics Committee (HREC).

ANZCTR listing: ACTRN12620000239965

JDRF
JDRF